Category Archives: Patents

Healthcare Groups Challenge Patents On Three New Hep-C Drugs In India

Source: Business World The patent challenges could remove barriers to production and distribution of affordable generic versions of direct-acting antiviral medicines, which are currently sold at very high prices Patient and healthcare aid groups, including I-MAK and Delhi Network of … Continue reading

Posted in Evergreening, Hepatitis C, Patent Opposition, Sofosbuvir, Uncategorized | Tagged , , | Leave a comment

Healthcare and patient groups oppose patents on crucial hepatitis C drugs

By Rupali Mukherjee, The Times of India  MUMBAI: Healthcare aid and patient groups have come together in patent courts to fight against “abusive strategies” of Big Pharma, to ensure access to affordable treatment in hepatitis C. The Initiative for Medicines, … Continue reading

Posted in Evergreening, Hepatitis C, Patent Opposition, Sofosbuvir, Uncategorized | Tagged , | Leave a comment

Flawed patents on hepatitis C drugs latest to be challenged in global push for access

Source: MSF Access Campaign New Delhi/New York, 14 February 2017–Five new challenges against patents on crucial new medicines to treat hepatitis C filed in India and Argentina are the latest in a global push to ensure access to affordable treatment. … Continue reading

Posted in Evergreening, Hepatitis C, Patent Opposition, Sofosbuvir, Uncategorized | Tagged , , | Leave a comment

TPP is dead, but its legacy lives on

By Arjun Jayadeva, The HinduThe Hindu | February 9, 2017 The Trans-Pacific Partnership was dead long before Donald Trump signed his executive order. But its damaging aspects, like stringent IP provisions, have just migrated to other agreements U.S. President Donald Trump’s … Continue reading

Posted in Data Exclusivity, Evergreening, Patent Term Extension, Regional Comprehensive Economic Partnership, TPP, Uncategorized | Leave a comment

European Commission publishes negotiating proposals for EU-Indonesia trade deal

It is important to note that the EU proposals on IP are TRIPS-plus in multiple regards and would surely reduce policy space in Indonesia and negatively impact access to affordable medicines.  Even a preliminary review of the proposal reveals: A … Continue reading

Posted in IPR Enforcement, Patent Term Extension, TRIPS, TRIPS flexibilities, TRIPS plus, Uncategorized | Leave a comment

Refuse trade, investment provisions that threaten access to affordable meds

Positive Malaysian Treatment Access & Advocacy Group (MTAAG+) calls on the Malaysian government to reject trade and investment agreement provisions that threaten access to affordable medicines. MTAAG+ asserts the need to make its position and demand known because of the … Continue reading

Posted in Data Exclusivity, Patent Term Extension, Regional Comprehensive Economic Partnership, TPP, TRIPS, TRIPS plus, Uncategorized | Leave a comment

President-Elect Trump Says the TPP is Dead, but What Now for IP?

By Sirena Rubinoff, IPWatchdog |December 15, 2016 President-Elect Donald Trump has announced that he will withdraw the United States from the Trans-Pacific Partnership (TPP) agreement on his first day in office. So ends more than five years of often heated negotiations … Continue reading

Posted in Data Exclusivity, Patent, Patent Term Extension, TPP, Uncategorized | Leave a comment